Author

Anna M Bielecka

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. - Cited by 4,526 - melanoma - cancer stem cells - immunotherapy - sarcoma - renal cell cancer

Biography

Dr. Anna M Bielecka is currently working at Pharmacology Medical  Department. Anna M Bielecka is research interests includes Pharmacology Medical  in High-glycolytic tumors. Anna M Bielecka serving as an editorial member and reviewer of several international reputed journals.Anna M Bielecka has successfully completed his Administrative responsibilities.Anna M Bielecka has authored of many research articles/books related to Medicine.
Title
Cited by
Year
TP53 in Biology and Treatment of Osteosarcoma
KJ Synoradzki, E Bartnik, AM Czarnecka, M Fiedorowicz, W Firlej, ...Cancers 13 (17), 4284, 2021202
23
2021
Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
K Stachyra, M Dudzisz-Śledź, E Bylina, A Szumera-Ciećkiewicz, ...International Journal of Molecular Sciences (12), 6305, 2021202
22
2021
Combined preoperative hypofractionated radiotherapy with doxorubicin-ifosfamide chemotherapy in marginally resectable soft tissue sarcomas: results of a phase II clinical trial
MJ Spałek, H Koseła-Paterczyk, A Borkowska, M Wągrodzki, ...International Journal of Radiation Oncology* Biology* Physics, 2021202
13
2021
The management of radiation-induced sarcomas: a cohort analysis from a sarcoma tertiary center
MJ Spałek, AM Czarnecka, P RutkowskiJournal of clinical medicine (4), 694, 2021202
10
2021
Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
I Płachta, M Kleibert, AM Czarnecka, M Spałek, A Szumera-Ciećkiewicz, ...International Journal of Molecular Sciences 22 (9), 4759, 2021202
10
2021
Imaging of Uveal Melanoma—Current Standard and Methods in Development
M Solnik, N Paduszyńska, AM Czarnecka, KJ Synoradzki, YA Yousef, ...Cancers 14 (13), 3147, 2022202
10
2022
Radiotherapy in the Management of Pediatric and Adult Osteosarcomas: A Multi-Institutional Cohort Analysis
MJ Spałek, J Poleszczuk, AM Czarnecka, M Dudzisz-Śledź, ...Cells 10 (2), 366, 2021202
9
2021
Expert recommendations on diagnostic-therapeutic management of melanoma patients
P Rutkowski, PJ Wysocki, K Kozak, A Nasierowska-Guttmejer, A Jeziorski, ...Oncology in Clinical Practice, 2022202
9
2022
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland
B Cybulska-Stopa, R Pacholczak-Madej, G Kamińska-Winciorek, M Ziętek, ...Immunotherapy 13 (4), 27-307, 2021202
9
2021
Efficacy of Sirolimus Treatment in PEComa–10 Years of Practice Perspective
T Świtaj, A Sobiborowicz, P Teterycz, A Klimczak, D Makuła, M Wągrodzki, ...Journal of Clinical Medicine 10 (16), 3705, 2021202
9
2021
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic …
B Cybulska-Stopa, M Ziętek, AM Czarnecka, K Piejko, R Dziura, Ł Galus, ...Journal of Dermatological Treatment, 1-24, 2021202
7
2021
What is the best front-line approach in patients with desmoid fibromatosis?–A retrospective analysis from a reference center
P Sobczuk, IM Agnieszczak, W Grycuk, AM Czarnecka, T Świtaj, ...European Journal of Surgical Oncology, 2021202
7
2021
Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network
A Smrke, AM Frezza, C Giani, N Somaiah, M Brahmi, AM Czarnecka, ...ESMO open 7 (3), 100522, 2022202
6
2022
New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
K Bilmin, KJ Synoradzki, AM Czarnecka, MJ Spałek, T Kujawska, M Solnik, ...Preprints, 2021202
6
2021
Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function
Ł Mielczarek, A Brodziak, P Sobczuk, M Kawecki, ...Cancer chemotherapy and pharmacology, 1-20, 2021202
6
2021
Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: A real-world evidence
AM Czarnecka, P Sobczuk, P Rogala, T Świtaj, J Placzke, K Kozak, ...Cancer Immunology, Immunotherapy, 1-10, 2022202
5
2022
Hyperpolarized 13C tracers: Technical advancements and perspectives for clinical applications
M Fiedorowicz, M Wieteska, K Rylewicz, B Kossowski, ...Biocybernetics and Biomedical Engineering, 2021202
5
2021
Treatment of Locally Advanced Merkel Cell Carcinoma—A Multi-Center Study
M Dudzisz-Sledz, P Sobczuk, K Kozak, T Switaj, H Kosela-Paterczyk, ...Cancers 1 (2), 22, 2022202
4
2022
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III BD or IV Stage BRAF V600 Mutation-Positive Melanoma
AM Czarnecka, K Ostaszewski, A Borkowska, A Szumera-Ciećkiewicz, ...Cancers 1 (1), 110, 2022202
4
2022
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
P Rogala, AM Czarnecka, B Cybulska-Stopa, K Ostaszewski, K Piejko, ...Journal of Clinical Medicine 11 (8), 229, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=pJBkMKcAAAAJ&hl=en

Cited by
Citations 4526
h-index 36
i10-index 107
Recommended Journals
Open Access Journals